Navigation Links
Abraxis BioScience Presents Pre-Clinical Findings That Support Role,of SPARC Expression in Cancer and the Role of the Nanoparticle,Albumin Bound (nab) Technology Platform in Targeting the Pathway

for ABRAXANE(R) (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease in 2005, its first product developed using the nab technology. Studies are ongoing to evaluate several other therapeutic candidates that employ the nab technology including nab-docetaxel (ABI-008), nab-rapamycin mTOR inhibitor (ABI 009), and nab-17AAG HSP90 inhibitor (ABI 010), among others.

About ABRAXANE (R)

The U.S. Food and Drug Administration approved ABRAXANE (R) for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in January 2005 for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. The most serious adverse events associated with ABRAXANE in the randomized metastatic breast cancer study for which FDA approval was based included neutropenia, anemia, infections, sensory neuropathy, nausea, vomiting, and myalgia/arthralgia. Other common adverse reactions included anemia, asthenia, diarrhea, ocular/visual disturbances, fluid retention, alopecia, hepatic dysfunction, mucositis, and renal dysfunction. For the full prescribing information for ABRAXANE(R), please visit www.abraxane.com.

ABRAXANE was developed by Abraxis BioScience, Inc. ABRAXANE is marketed in the United States under a co-promotion agreement between Abraxis BioScience, Inc. and AstraZeneca Pharmaceuticals LP.

About Abraxis BioScience, Inc.

Abraxis BioScience, Inc. is an integrated global biopharmaceutical company dedicated to meeting the needs of critically ill patients. The company develops, manufactures and markets one of the broadest portfolios of injectable products and leverages revolutionary technology such as its nab(TM) platform t
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Abraxis BioScience Presents Results from Pre-Clinical Study That Demonstrates nab-Rapamycins Robust Antitumor Properties and Ability to Target Intracellular Sites Such as the mTOR Pathway
2. Abraxis BioScience Presents Data from Pre-Clinical Study That Provide Evidence for Chemotherapy-Induced Angiogenesis and Rationale for Combining nab-Paclitaxel (Abraxane) with Anti-Angiogenic Agents to Increase Tumor Response
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
5. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
6. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
7. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
8. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
9. ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent
10. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
11. IR BioSciences Announces Data Demonstrating Radilex Stimulation of Stem Cells Results in Hematopoietic Recovery Following Lethal Irradiation
Post Your Comments:
(Date:1/14/2014)... 14, 2014 InformEx, North America,s ... chemistry, will hold the 30 th edition of its ... Convention Center from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ... pharmaceutical, fine chemical and specialty chemical companies will take part ...
(Date:1/14/2014)... 14, 2014 Animal Emergency Critical Care, a LifeCentre partner practice, ... is the first in Loudoun County ... Dr. Susan M. Barnes , Medical Director, is a ... Dr. Cole Taylor , are avid scuba divers. "As altitude ...
(Date:1/14/2014)... PORT WASHINGTON, New York , January 14, ... the leading provider of Closed System Transfer Devices (CSTD) for hazardous drugs, ... sales growth for the fourth straight year.   ... of exposure for pharmacy technicians, pharmacists, nurses and ...
Breaking Medicine Technology:Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2Equashield's Sales Grow by 60% in 2013 2
... , NEW BRUNSWICK, N.J., Nov. 12 Senesco ... SNT ) announced today that Catherine Taylor, ... presenting pre-clinical stability and biological activity data on ... 2009 American Association for Cancer Research (AACR)-National Cancer ...
... Thoratec Corporation (Nasdaq: THOR ), a world leader ... and restore failing hearts, said today that it will ... HeartMate II Destination Therapy clinical trial that will be ... the American Heart Association(AHA) Scientific Sessions 2009. , The ...
Cached Medicine Technology:Senesco Presents Pre-Clinical Stability and Biological Activity Data on SNS-01 at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference 2Senesco Presents Pre-Clinical Stability and Biological Activity Data on SNS-01 at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference 3
(Date:7/10/2014)... the "Mississippi baby" an infant seemingly cured of HIV ... remission of HIV infection in The New England Journal ... after more than two years of not taking antiretroviral therapy ... and researchers involved in the case. , "Certainly, ... child, the medical staff involved in the child,s care, and ...
(Date:7/10/2014)... research at the University of Huddersfield could help to ... emulsion-based food products such as butter, mayonnaise, yoghurt ... gain an international profile for her work. , Katerina ... at the University and now she has embarked on ... Dr Vassilis Kontogiorgos, she is investigating the potential of ...
(Date:7/10/2014)... with localized prostate cancer were more likely to ... less effective treatments and survived for shorter times ... a UCLA study has found. , The negative ... such as bias against the mentally ill, depression,s ... lack of investment in his general health and ...
(Date:7/9/2014)... 2014) If you think winning is one of the ... again: Winning along with other mental bonuses ranked near the ... into one of 11 big fun factors, according to a ... important when it comes to the "fun" factor, very little ... goes into this elusive conceptuntil now. , The results of ...
(Date:7/9/2014)... (PHILADELPHIA) Researchers at the Perelman School of Medicine ... Roswell Park Cancer Institute have received an $8 million ... the effects of photodynamic light therapy (PDT) in patients ... cancer that most often manifests itself in the lining ... exposure to asbestos. The grant will fund a clinical ...
Breaking Medicine News(10 mins):Health News:'Mississippi Baby' now has detectable HIV, researchers find 2Health News:'Mississippi Baby' now has detectable HIV, researchers find 3Health News:World interest in research work on the benefits of the Okra plant 2Health News:Depressed men with prostate cancer are diagnosed later stage, get less effective therapies 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 3Health News:Penn mesothelioma program receives $8 million NCI grant 2
... 25, 2010 (Toronto) A new study from The Centre ... accounts for 43% of all cigarettes consumed by Ontario high ... The study, published in the current edition of Tobacco ... and found that of high school daily smokers, 50% smoked ...
... Amanda Gardner HealthDay Reporter , FRIDAY, Oct. 22 ... Staphylococcus aureus , or MRSA, a common bacterial infection acquired ... presented at the annual meeting of the Infectious Diseases Society ... of the people it infected within 30 days, the study ...
... DETROIT Patients admitted to the hospital for the ... a first line of defense with the potent antibiotic ... according to a Henry Ford Hospital study. For ... whether vancomycin or so-called B-lactam antibiotics like penicillin or ...
... Reporter , FRIDAY, Oct. 22 (HealthDay News) -- You might have seen ... an Iraq War vet with severe burns across much of his body ... his injuries. Martinez, 27, earned the right to play that role ... month into his first Iraq deployment as a real-life Army soldier, his ...
... School of Medicine, led by Lucila Ohno-Machado, MD, PhD, ... Department of Medicine, have received two federal grants totaling ... gather, analyze, use and share vast, ever-increasing amounts of ... over five years will create a national center for ...
... new cancer research being released at the American Society for ... 31 through November 4, 2010, in San Diego. For ... Napoli at nicolen@astro.org or Beth Bukata at ... 1:00 p.m. Eastern time. Adding radiation to hormone ...
Cached Medicine News:Health News:Contraband cigarettes main source of supply for Ontario youth 2Health News:MRSA Strain With Outbreak Potential Among Reports at Disease Conference 2Health News:MRSA Strain With Outbreak Potential Among Reports at Disease Conference 3Health News:Iraq War Vet, Daytime TV Star Turns Scars Into Inspiration 2Health News:Iraq War Vet, Daytime TV Star Turns Scars Into Inspiration 3Health News:UC San Diego receives 2 major biomedical informatics grants 2Health News:UC San Diego receives 2 major biomedical informatics grants 3Health News:UC San Diego receives 2 major biomedical informatics grants 4Health News:Practice-changing studies on how oncologists treat cancer to be presented at ASTRO Annual Meeting 2
Triangular 0.5 mm angled tip with 4 mm flat surface. Round knurled handle with dull finish. Tip angle: 150o....
Angled blade and flat serrated handle with polished finish. Blade: 1 mm x 10 mm....
Angled tip with gently curved blade. Short hexagonal handle with polished finish. 0.5 mm x 15 mm tip....
0.5 mm short 90 degree angled tip with black ebonized shaft. Titanium handle with position reference indicator. Shaft length 52 mm, handle length 100 mm....
Medicine Products: